International Journal of Tuberculosis and Lung Disease

Article	Citations
Dr Christopher Zishiri	154
Travel reimbursements, distance to health facility and preventive treatment cascade for drug-resistant TB	87
Screening of refugees from Ukraine for TB: a TBnet survey	54
Decentralising DOT for drug-susceptible TB from the health facilities to the community level in Togo	47
TB infection in adults with diabetes mellitus in Uganda	44
Clinical profile and outcomes of paediatric central nervous system tuberculomas	42
Launch of a second wave of IJTLD Clinical Standards for Lung Health	34
TB-related deaths among adults in Guinea-Bissau	32
Ethambutol-induced optic neuropathy: should we mandate ophthalmic examination in TB treatment?	30
Reply to ‘Estimating TB survival ‐ mind the immortal-time gap’	29
The effect of antenatal isoniazid preventive therapy on birth outcomes in Western Kenya	28
Atorvastatin to reduce bacillary load and attenuate lung damage in TB patients	26
CAD4TB software updates: different triaging thresholds require caution by users and regulation by authorities	21
WHO target product profiles for TB preventive treatment	21
Use of a molecular bacterial load assay to distinguish between active TB and post-TB lung disease	19
TB in ageing populations: lessons from Japan and Korea	18
The impact of sputum quality on Xpert positivity in active case-finding for TB	18
Targeted therapeutic drug monitoring identifies frequent under-dosing of TB drugs	17
Latent TB and depressive symptoms in household contacts of persons with active TB	17
Cost-effectiveness of pretomanid-based regimen for highly drug- resistant TB in a low-burden setting	17
CFU counting may underestimate TB bacilli number of blood, biasing limit of detection estimates in spiking experiments	17
Haematological indicators of mortality in people with community-acquired pneumonia living at high altitude	16
Yield of community outreach events for TB screening	16
Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries	16
The COVID-19 pandemic does not bode well for TB control	15

Lichenoid drug eruption in patients on anti-TB therapy in a high HIV prevalence setting	14
Assessing patient satisfaction with video-supported therapy for drug-susceptible TB treatment	14
Standards for clinical trials for treating TB	14
Occupational transmission of TB infection during autopsy	14
Advantages and limitations of virtual multi-disciplinary team meetings on difficult-to-treat mycobacteria	14
Accessibility and TB patient satisfaction in Nigeria	14
Literature Highlights	13
Are schools prepared to manage students with an asthma attack?	13
Introduction of the Simple One-Step stool Xpert Ultra method to detect TB in children and adults	13
Perceived stigma among people with TB and household contacts	13
Assessment of TB patient cost – what about the mitigation strategy?	13
Prevalence of chronic airflow obstruction in sub-Saharan Africa	12
Performance of spirometry assessment at TB diagnosis	12
TB disease yield from household contact screening of TB index patients in Pakistan	12
Gender differences in health-seeking behaviour, diagnosis and treatment for TB	12
A cohort study exploring variables associated with mortality in critically ill TB patients	12
TB testing in HIV-positive patients prior to antiretroviral treatment	12
A novel method for contact tracing for TB at household and community level	11
Incidence of TB among kidney transplant recipients in a setting with universal isoniazid prophylaxis	11
Health status of Italian children living close to cultivations sprayed with pesticides	11
Patterns of TB transmission in the United States, 2011–2017	11
Factors associated with false-negative for T-SPOT.TB in patients with TB disease	11
Paediatric TB care in the United Kingdom	10
Initial experience with BPaL-based regimens to treat multidrug-resistant TB	10
Higher yield using an event-based vs. door-to-door approach for active case-finding for TB	10
Emphasis on post-TB lung disease and other sequelae of TB is good but a public health approach to TB is morally ambitious	10
Population attributable fraction for smoking and diabetes in TB	10
Decentralising TB diagnosis and contact management: impact on detection and preventive treatment in children	10
Treatment outcomes and safety of bedaquiline, delamanid, and linezolid in multidrug-resistant TB	10
Impact of COVID-19 on extrapulmonary TB and the benefit of decentralised TB services	9
Clinical standards for the diagnosis and management of asthma in low- and middle-income countries	9
Medical management of large and multiple pulmonary echinococcal cysts	9
Risk factors for severe COPD exacerbation in Chinese adults	9
Post-TB lung disease: keep going beyond TB!	9
Post-hospitalisation respiratory and physical functions in patients with SARS-CoV-2 delta	9
Facilitators and barriers to adolescent participation in a TB clinical trial	9
Does distance to healthcare facility affect care-seeking for TB-related symptoms in Tanzania?	9
Updated guidelines for child and adolescent TB	9
Opportunities to prevent and manage undernutrition to amplify efforts to end TB	9
Cascade of care for people with TB and diabetes in India	8
Epidemiology, detection, diagnosis and treatment of TB in children in Kazakhstan	8
TB therapeutic drug monitoring – analysis of opportunities in Romania and Ukraine	8
The household economic burden of drug-susceptible TB diagnosis and treatment in The Gambia	8
Protecting healthcare workers from TB	8
Bedaquiline-based all-oral regimen for macrolide-resistant Mycobacterium abscessus pulmonary disease	8
Clinical features, microbiology and lung function in post-TB bronchiectasis compared to other aetiologies	8
TB notifications among citizens and non-citizens in Taiwan	8
Lower TB notification rates in later life in the same birth cohort, Japan, 1950–2020	8
Population pharmacokinetics of bedaquiline in patients with drug-resistant TB	8
The effect of systematic screening of the general population on TB case notification rates	8

Mortality and causes of death in non-tuberculous mycobacterial pulmonary disease	8
If you want to go far, go together: standardisation and data sharing in TB drug development	8
TB and chronic pulmonary aspergillosis: a few relevant points	7
Perceived stigma related to TB preventive therapy	7
Characteristics, risk factors and outcomes of critically ill patients with active TB	7
Financial impact of COVID-19 on TB patients in India	7
Cost of TB prevention and treatment in the Philippines in 2017	7
A scoping review of interventions to mitigate common non-communicable diseases among people with TB	7
Predictors of TB disease in HIV-exposed children from Southern Africa	7
Community-based intervention and health education to scale up TB preventive treatment for children	7
Evaluation of QFT-Plus performance using blood samples stored at room temperature	7
Use of computed tomography for the diagnosis of TB during a paediatric outbreak	7
Prevalence and determinants of chronic respiratory diseases in adults in rural Sudan	7
Effect of biological therapies on TB treatment outcomes	7
Paediatric formulations for the treatment of drug resistant TB: closing the gaps	7
Contribution of Xpert® MTB/RIF to pediatric TB diagnosis in Mozambique	7
Proportions of Xpert MTB/RIF Ultra ‘trace’ results vary widely among different populations with presumptive TB	7
Meeting of two pandemics in prison: a challenging event in a challenging environment	7
TB prevalence among pregnant women with HIV in Rio de Janeiro, Brazil	7
A systematic review on the effect of diabetes mellitus on the pharmacokinetics of TB drugs	6
Diabetes characteristics and long-term management needs in diabetic TB patients	6
Cutaneous adverse drug reactions to fixed-dose combination treatments for TB	6
Evaluation of testing face-mask filter samples with LAMP shows high rates of detection in pulmonary TB	6
TB and COVID-19 co-infection in a pulmonology hospital	6
Responding to the post-pandemic crisis: post-exposure prophylaxis for TB	6
TB screening of Ukrainian refugees in Germany	6
New diagnostics for the spectrum of asymptomatic TB: from infection to subclinical disease	6
Use of stool swabs in molecular transport media increases access to Xpert Ultra testing for TB in children	6
High prevalence of multidrug-resistant TB among household contacts in a high burden setting	6
Estimating TB survival ‐ mind the immortal-time gap	6
Exhaled breath specimens subjected to point-of-care lipoarabinomannan testing	6
Supplementary inspired oxygen fraction is a simple clinical tool that predicts clinical deterioration	6
Extemporaneously compounded liquid formulations of clofazimine	6
WHO drug-resistant TB guidelines 2022: what is new?	6
TB mortality in low-incidence countries: can we reduce it further?	6
Bronchiectasis exacerbations: certainties and future challenges	6
Fluoroquinolone preventive therapy for children exposed to MDR-TB	6
National approaches to TB care in adolescents	6
Rapid molecular diagnostics to detect resistance to second-line anti-TB drugs	6
Time to integrate epidemiological and economic models for TB	6
The high costs facing TB-affected households in Mali	6
Mycobacterium tuberculosis genotypes isolated from clinical specimens of extrapulmonary TB	6
A new understanding of clinical patterns in post-TB lung disease	6
Glutathione and N-acetylcysteine in TB management	6
Sputum pooling for rapid and cost-effective active case-finding for TB in prisons	6
Determinants of treatment outcomes in patients with multidrug-resistant TB	6
Factors associated with patient delay in the diagnosis of TB – a study of health-seeking behaviour	5
Establishing proof of concept for utility of Trueprep®-extracted DNA in line-probe assay testing	5
Prevalence of and risk factors for depressive symptoms in non-tuberculous mycobacterial pulmonary disease	5
Geographical differences in chronic obstructive pulmonary disease mortality trends by sex, Spain, 1980–2021	5
Evidence and ethical considerations for the treatment of contacts exposed to drug-resistant TB	5
Metabolic characterisation of adult Ugandan patients with TB and diabetes mellitus comorbidity	5
After DOT, the brave new world?	5
Early mortality during rifampicin-resistant TB treatment	5
Family directly observed therapy for children with drug-resistant TB	5
First report of multidrug-resistant M. tuberculosis Beijing strain isolated from the indigenous population in Tunisia	5
Is it time for new fixed-dose combinations and revised weight bands for children with drug-susceptible TB?	5
Stool-based Xpert testing for diagnosis of TB in children and critically ill adults	5
Potential use of nasopharyngeal aspirate for pediatric TB diagnosis	5
The rise of artificial intelligence reading of chest X-rays for enhanced TB diagnosis and elimination	5
TB screening, prevention and treatment cascade in a Malawi prison	5
Implementation of modified, all-oral shorter TB regimens in Armenia	5
Early line-probe assay using DNA specimens in patients with pulmonary TB	5
An epidemiological analysis of TB trends in native and migrant populations, New Mexico, 1993–2021	5
A study of persistent symptoms and pulmonary function at 3 months post moderate or severe COVID-19 in Angola	5
Impact of the COVID-19 pandemic on TB infection testing	5
A comprehensive person-centred TB care model, from malnutrition to mental health	5
Evaluation of the MolecuTech® REBA MTB-XMDR kit for detection of pre-extensively drug-resistant TB	5
Quality assessment of clinical practice guidelines for the management of wheezing disorders in children	5
Efflux pump gene expression study using RNA-seq in multidrug-resistant TB	5
Approaches and processes for paediatric chest X-ray classification used in the SHINE TB treatment-shortening trial	5
Lessons learned from treating drug-resistant TB and how to apply these to drug-susceptible TB	5
Factors associated with presenting to private sector care providers at the onset of TB symptoms	5
Literature Highlights	5
TB screening of children from Ukraine in Germany	5
Diabetes mellitus and TB – finding strategies to reduce the double burden of disease	5
Interventions to enhance treatment adherence and retention in care for HIV-TB	5
Artificial intelligence for TB education and counselling: a modified Delphi consensus	4
Long-term follow-up of persons diagnosed with multidrug-resistant TB in Chennai, India, 2013–2020	4
The urgent need to improve on low implementation rates for TB preventive treatment for people living with HIV	4

Risk factors for the isolation of Haemophilus influenzae in patients with stable chronic obstructive pulmonary disease	4
Use of rapid molecular TB diagnostics for incarcerated people in Brazil	4
Risk factors in ICU patients with initial acquisition of carbapenemase-resistant Klebsiella Pneumoniae	4
National survey on the impact of the war in Ukraine on TB diagnostics and treatment services in 2022	4
Factors associated with screening failure and study withdrawal in multidrug-resistant TB	4
Contribution of post-infectious bronchiolitis obliterans to non-cystic fibrosis bronchiectasis in children	4
Highlighting the characteristics of TB disease in older people	4
Outcomes for people with TB by disease severity at presentation	4
Post-TB bronchiectasis: clinical characteristics and microbiology	4
Eosinophils in bronchiectasis: searching for a new endotype	4
Attrition in the treatment cascade among elderly patients with multidrug-resistant TB	4
Bridging the gap: key evidence needed to strengthen global policies to end TB	4
Clinical outcomes in comorbid COVID-19 and TB cases	4
Factors associated with referrals for directly observed treatment and unsuccessful treatment	4
Household air pollution and COPD: cause and effect or confounding by other aspects of poverty?	4
The economic burden of TB-affected households in DR Congo	4
Predictive value of neutrophil-to-lymphocyte ratio in severe pulmonary infection: sex-specific cut-off values needed	4
Introduction of new drugs for drug-resistant TB in Iraq	4
Therapeutic drug monitoring for isoniazid and rifampicin exposure	4
Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications	4
Programmatic implications of a sub-national TB prevalence survey in India	4
Chronic respiratory disease in adult outpatients in three African countries: a cross-sectional study	4
SMaRT-PCR: sampling using masks and RT-PCR, a non-invasive diagnostic tool for paediatric pulmonary TB	4
Borderline T-SPOT.TB results: test reliability, patient characteristics, and TB progression	4
Concomitant pulmonary disease is common among patients with extrapulmonary TB	4
Impact of Rv0678 mutations on patients with drug-resistant TB treated with bedaquiline	4